Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Companies / Fulgent Genetics
Company

Fulgent Genetics

Tracked across 1 events · 8 articles · First seen May 21, 2026 · Last active Jun 01, 2026

Sentiment
75
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 75
Tech
Fulgent FID-007 Phase 2 Results
Fulgent Genetics announced and presented updated interim data from its open-label, randomized Phase 2 study of FID-007 in combination with Cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at the…
Impact: Fulgent Genetics announced positive interim results from its Phase 2 study of FID-007, which could significantly advance its therapeutic development business and potentially lead to a Phase 3 study. This positive data could increase investor confidence and its stock price.
May 21, 2026 · 8 articles
Key Actions (2)
90 Fulgent Genetics presented updated dataFulgent FID-007 Phase 2 Results
80 Fulgent Genetics announced abstract releaseFulgent FID-007 Phase 2 Results
NEWSDESK
Track Fulgent Genetics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.